State Medicaid and GLP-1s: Who Covers What

If you are on Medicaid and want a GLP-1 for weight management, the most important thing to understand is that you are not dealing with one national rule. You are dealing with fifty separate decisions, and in 2026 several of them changed in the same direction: away from coverage.

This article explains the legal structure, the current state of play, why states are cutting, and what federal programs were supposed to fix it. It is not medical advice and it is not legal advice about your benefits. Your state Medicaid agency’s preferred drug list and your prescriber are the authorities on your own coverage.

This page contains no dosing guidance. It does not describe what dose to take, how to change a dose, when to start or stop a medication, or how to combine one with another. Those are set by the FDA-approved prescribing information and Instructions for Use for each product, by your own prescription, and by your provider.

The rule that explains everything

Under the Medicaid Drug Rebate Program, state Medicaid programs must cover nearly all of a participating manufacturer’s FDA-approved drugs for medically accepted indications [1]. That is a strong requirement, and it is why GLP-1s are broadly available through Medicaid for type 2 diabetes.

But federal law carves out an exception: states may choose whether to cover drugs used for weight loss [1]. That single optional-coverage clause is the reason your access depends on your zip code.

So the practical structure is:

Use	Medicaid coverage
Type 2 diabetes	Required in effect, in nearly all states, usually with prior authorization
Other FDA-approved indications outside weight loss (for example cardiovascular risk reduction, sleep apnea, MASH)	Generally required as medically accepted indications
Obesity or weight loss alone	Optional by state
Any medically necessary service for enrollees under 21	Protected under federal EPSDT rules

Sources: KFF Medicaid analysis [1]; KFF BALANCE explainer [2].

How many states cover GLP-1s for obesity?

The count fell sharply at the start of 2026.

• October 2025: 16 state Medicaid programs covered GLP-1s for obesity treatment, according to KFF’s 2025 Medicaid budget survey [1].
• January 2026: 13 state Medicaid fee-for-service programs covered them [1].
• April 2026: still 13, per KFF, with independent reviews splitting that into roughly 10 states with standard prior-authorization coverage and about 3 with heavier restrictions [3].

Coverage is almost always subject to utilization controls such as prior authorization, step therapy or BMI thresholds, which can limit access further even where coverage technically exists [1].

Which states cut, and when

Four states ended obesity GLP-1 coverage effective January 1, 2026 [1]:

• California
• New Hampshire
• Pennsylvania
• South Carolina

KFF attributes the cuts to state budget challenges and the cost of coverage [1].

North Carolina is the instructive case. It eliminated GLP-1 coverage for obesity beginning October 2025 during a legislative budget stalemate, then reinstated coverage in December 2025, which is what brought the national count back to 13 as of January 2026 [1].

Colorado and West Virginia have also been reported as removing GLP-1 medications for weight loss [4]. That claim rests on a secondary compilation rather than a state or KFF primary source and should be treated as unverified; neither state appears on KFF’s January 2026 covering list, which is consistent with it but does not confirm the timing.

KFF’s map of the 13 fee-for-service programs covering GLP-1s for obesity treatment as of January 2026 names Delaware, Kansas, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, North Carolina, Rhode Island, Tennessee, Utah, Virginia and Wisconsin [1]. Earlier drafts of this page listed only ten of those states; Massachusetts, North Carolina and Rhode Island belong on the list. Stateline reported in April 2026 that additional states were weighing whether to drop coverage [5].

Because these lists change with budget cycles, verify your own state’s current preferred drug list rather than relying on any article’s snapshot.

Why states are cutting

The spending curve is the whole argument.

Year	Medicaid GLP-1 prescriptions	Gross Medicaid GLP-1 spending
2019	about 1 million	about USD 1 billion
2024	more than 8 million	about USD 9 billion

Source: KFF [1].

That is roughly a sevenfold rise in prescriptions and a ninefold rise in gross spending in five years. By 2024, GLP-1s represented about 1% of all Medicaid prescriptions but more than 8% of Medicaid prescription drug spending before rebates [1].

Two caveats are important and often left out of state-level debates.

First, gross spending is not net spending. Medicaid collects substantial statutory and supplemental rebates, so the actual state and federal outlay is materially lower than the gross figure. KFF reports gross because net rebate amounts are confidential.

Second, the eligible population is unusually large. KFF has reported that nearly 40% of adults and about a quarter of children covered by Medicaid have obesity [3]. A benefit with that denominator is expensive at almost any unit price, which is exactly why states treat it as a budget decision rather than a formulary decision.

What happens to people mid-treatment

This is the part that gets the least attention and matters most clinically.

When a state ends coverage, people already on treatment are affected along with new starters.

What the published evidence says about stopping: the withdrawal extension of the STEP 1 trial reported that participants regained roughly two-thirds of their lost weight in the year after semaglutide was discontinued, and SURMOUNT-4 reported substantial regain after tirzepatide was withdrawn [17][18]. The FDA-approved labeling for these products describes chronic weight management rather than a fixed course.

Those are study findings, not instructions. A coverage change is an administrative event, and decisions about continuing, changing or stopping any medication belong to a patient and their prescriber, who know the diagnosis and history. State agencies also differ in what transition or continuity-of-care provisions they offer, and that is a question for the agency.

The federal programs that were supposed to help

The Trump administration announced two related initiatives in late 2025 aimed at exactly this gap.

The November 2025 pricing deals

In November 2025 the administration announced agreements with Eli Lilly and Novo Nordisk to reduce GLP-1 prices for Medicare and Medicaid, with government prices for currently available injectable GLP-1s falling to about USD 245 per month [6][7].

The BALANCE model

On December 23, 2025, CMS unveiled BALANCE, a voluntary payment model intended to expand obesity drug access in Medicaid and Medicare Part D through negotiated lower prices, standardized coverage criteria and lifestyle support [6][8].

The key design facts [2][8]:

• Participation is voluntary for manufacturers, state Medicaid agencies and Part D plans
• Both Eli Lilly and Novo Nordisk agreed to participate as manufacturers; CMS negotiated pricing, cost sharing, rebate calculation, coverage criteria and lifestyle-support terms with them during a pre-implementation period in early 2026 [2]
• Medicaid coverage under BALANCE could launch as early as May 2026
• State Medicaid agencies had to submit applications by July 31, 2026, and may begin participating on a date of their choosing between May 1, 2026 and January 1, 2027; a state that does not join by January 1, 2027 can only be admitted at CMS’s discretion [2]
• The Medicaid arm runs five years, through December 2031
• Medicare Part D participation was originally targeted for January 2027

Two things have since happened, and they point in opposite directions.

The Medicare half was shelved. In May 2026 CMS said the BALANCE model would not launch in Medicare Part D in 2027 after all, and extended the separate Medicare GLP-1 Bridge demonstration through December 31, 2027 instead [2]. That delay is indefinite, not a rescheduling to a named date.

The Medicaid half is still live but publicly opaque. The state application window closed July 31, 2026. As of this writing CMS has not publicly named any participating state, and the CMS model page listed the number of participants as not applicable [3]. So the honest status is that the Medicaid arm continues on paper while no state participation has been confirmed in public — not that the model has been formally abandoned.

A Health Affairs Forefront piece published in 2026 was titled, bluntly, “After BALANCE: Why Voluntary Coverage For Obesity Drugs Failed And What Comes Next,” and argued that CMS rulemaking or Congress should remove the Medicare coverage exclusion outright [9]. That page returned an access error on retrieval, so its thesis is recorded from its title and from secondary summaries rather than from the full argument.

The Medicare GLP-1 Bridge

CMS announced the Medicare GLP-1 Bridge alongside BALANCE in December 2025, as a short-term demonstration to carry Medicare beneficiaries until the BALANCE Part D arm started. It was originally scheduled to run July 1 through December 31, 2026. When CMS shelved the Part D arm in May 2026, it extended the Bridge through December 31, 2027, with a flat USD 50 monthly copay [2][8]. It is nationwide and does not require Part D sponsors to opt in [2]. That solved the Medicare half of the problem on a temporary basis. It did nothing for Medicaid.

The result, as of September 2026, is an odd inversion: a Medicare beneficiary in any state can get certain GLP-1s for USD 50 a month, while a Medicaid enrollee in most states cannot get them for obesity at all.

What states are doing legislatively

With federal coverage unsettled, several states legislated directly in 2026.

California passed SB 1089, the Preventive Treatment Health Care Act, which was enrolled and presented to the Governor on September 3, 2026 [10]. It directs the California Health and Human Services Agency to seek partnerships to increase competition, lower prices and address supply shortages for at least one FDA-approved GLP-1 anti-obesity medication under the state’s CalRx program [11]. An earlier, more ambitious version would have required CalPERS, which insures about 1.3 million public employees and retirees, to cover GLP-1 drugs; CalPERS opposed it, estimating premiums would rise about USD 28 per member per month [10]. The bill also would authorize employers with 100 or more employees to negotiate GLP-1 discounts directly with manufacturers [12]. Note the timing: California cut Medicaid obesity coverage in January 2026 and then passed a GLP-1 price-competition bill in September 2026.

Colorado took up SB26-066, regulating the sale, transfer and distribution of compounded weight-loss medication [13].

Maryland considered a bill in March 2026 that would have attached about USD 449 million in annual Medicaid funds to expanded obesity treatment coverage including GLP-1s, intensive behavioral therapy and bariatric surgery, in a session where lawmakers were closing a USD 1.4 billion shortfall [14].

Arkansas saw HB 1332 in the 2025 session, which would have required Medicaid to document the cost of obesity-related conditions and required insurers to offer optional anti-obesity medication coverage. It failed in Senate committee [8].

Practical guidance if you are on Medicaid

None of this substitutes for talking to your prescriber and your state agency, but these are the questions worth asking:

1. What is my actual diagnosis on the prescription? GLP-1 coverage rules differ sharply between weight management and other approved indications. This is a clinical question for your prescriber, not something to manage on your own.
2. Is my state fee-for-service or managed care? KFF’s 13-state count is for fee-for-service programs; managed care organizations within a state may have their own rules.
3. Is there a prior authorization pathway? Most covering states require it, often with BMI and comorbidity criteria.
4. Am I or is my child under 21? Federal EPSDT rules require coverage of medically necessary services for Medicaid enrollees under 21, which can apply where adult coverage is excluded [3].
5. If coverage ends, what does my state offer for transition? Ask before your current supply runs out, not after.
6. Who decides what happens to the prescription itself? Not this article, and not the coverage letter. Dosing, continuation and discontinuation are governed by the FDA-approved prescribing information and Instructions for Use for the specific product, by your own prescription, and by your prescriber’s clinical judgment. This page summarizes coverage policy only; it contains no dosing guidance of any kind.

What to watch next

Three things will determine whether the Medicaid picture improves or gets worse:

Whether CMS names any BALANCE state. The application window for state Medicaid agencies closed July 31, 2026, and participating states may start on a date of their choosing up to January 1, 2027. No state had been publicly identified as of this writing [2][3]. If names appear, they will appear on the CMS model page.

Whether the Medicare GLP-1 Bridge is extended past December 31, 2027, or replaced. If Congress passes the Treat and Reduce Obesity Act, which would lift the Medicare weight-loss exclusion, it would also reset the political framing for Medicaid. The Congressional Budget Office estimated in 2024 that Medicare coverage of anti-obesity medications would increase federal spending by about USD 35 billion over nine years, which is the main obstacle [15].

Whether falling prices change the math. Novo’s US list price for semaglutide products drops to USD 675 a month on January 1, 2027 [16], and the Medicare negotiated price for semaglutide takes effect the same day at USD 274 per 30-day supply, down from the USD 959 list price CMS used for comparison, a 71% cut [19]. Medicaid’s best-price rules mean that lower commercial and federal prices generally flow through to Medicaid over time. A benefit that was unaffordable at USD 1,000 a month is a different budget question at USD 274.

---

Sources

1. KFF, “Medicaid Coverage of and Spending on GLP-1s.” https://www.kff.org/medicaid/medicaid-coverage-of-and-spending-on-glp-1s
2. KFF, “What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid.” https://www.kff.org/medicare/what-to-know-about-the-balance-model-for-glp-1s-in-medicare-and-medicaid
3. Medical Daily, “The Federal Deal to Cut Medicaid Prices on Weight Loss Drugs Still Names No Participating States.” https://www.medicaldaily.com/balance-model-medicaid-glp1-state-participation-coverage-gap-477723
4. StateVitals, “State Medicaid GLP-1 Coverage for Weight Loss 2026.” https://www.statevitals.us/blog/state-medicaid-glp1-coverage-weight-loss-2026
5. Stateline, “More states consider dropping GLP-1 weight loss drugs from Medicaid,” April 30, 2026. https://stateline.org/2026/04/30/more-states-consider-dropping-glp-1-weight-loss-drugs-from-medicaid
6. Reuters, “US health agency unveils weight-loss drug coverage model,” December 23, 2025. https://www.reuters.com/business/healthcare-pharmaceuticals/us-health-agency-expand-access-glp-1-weight-loss-drugs-2025-12-23
7. ACHI, “Trump Administration Announces New Voluntary Payment Model for Weight-Loss Drugs,” January 6, 2026. https://achi.net/newsroom/trump-administration-announces-new-voluntary-payment-model-for-weight-loss-drugs
8. CMS, “BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model.” https://www.cms.gov/priorities/innovation/innovation-models/balance
9. Health Affairs Forefront, “After BALANCE: Why Voluntary Coverage For Obesity Drugs Failed And What Comes Next.” https://www.healthaffairs.org/content/forefront/after-balance-why-voluntary-coverage-obesity-drugs-failed-and-comes-next
10. CalMatters, “California moves to expand access to GLP-1 weight-loss drugs,” August 2026. https://calmatters.org/health/2026/08/glp-weight-loss-cost-affordability-california
11. Digital Democracy, “SB 1089: Preventive Treatment Health Care Act.” https://calmatters.digitaldemocracy.org/bills/ca_202520260sb1089
12. LegiScan, “CA SB1089 2025-2026 Regular Session.” https://legiscan.com/CA/text/SB1089/id/3362915
13. Colorado General Assembly, “SB26-066 Regulation of Compounded Weight-Loss Medication.” https://leg.colorado.gov/bills/sb26-066
14. The Baltimore Sun (via social post), Maryland Senate obesity treatment coverage bill, March 2026. https://www.facebook.com/baltimoresun/posts/on-monday-senate-minority-leader-steve-hershey-asked-his-chamber-colleagues-to-p/1363457775828728
15. CNBC, “Medicare obesity drug GLP-1 coverage starting July 1,” June 30, 2026. https://www.cnbc.com/2026/06/30/medicare-obesity-drug-glp-1-coverage-starting-july-1.html
16. Medscape / Reuters, “Novo Nordisk to Halve US List Price Of Wegovy From 2027,” February 24, 2026. https://www.medscape.com/s/viewarticle/novo-nordisk-slash-us-list-prices-ozempic-and-wegovy-wsj-2026a10005sl
17. Wilding JPH et al., “Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension,” Diabetes, Obesity and Metabolism, 2022. https://pubmed.ncbi.nlm.nih.gov/35441470
18. Aronne LJ et al., “Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial,” JAMA, 2024. https://jamanetwork.com/journals/jama/fullarticle/2826524
19. CMS, “Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2027.” https://www.cms.gov/files/document/fact-sheet-negotiated-prices-ipay-2027.pdf